Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the genetic risk (or lack thereof) for lung cancer.

Interventional pulmonologist Dr. Jed Gorden reviews malignant pleural effusions (MPEs) are a common complication of lung cancer and some other cancers. TranscriptSo, I wanted to talk to you today about pleural effusions. Pleural effusions — it’s a complex term, and it’s a very common problem, so let

Dr. Jed Gorden describes the details of how a thoracentesis is performed in order to clarify the diagnosis and treat symptoms of a malignant pleural effusion (MPE). TranscriptWith the pleural fluid that’s built up around the lung — this fluid that exist in between the linings, or as we discussed

A tunneled pleural catheter is an excellent way to manage the symptoms of a recurrent malignant pleural effusion. Dr. Jed Gorden describes how it is placed and how it works. TranscriptSo we’re talking today about pleural fluid — fluid that resides around the lung, in-between this space that we’re

Dr. Jed Gorden reviews the technique of pleurodesis to manage the complication of recurrent malignant pleural effusion (MPE). TranscriptSo we’re talking today about pleural fluid, the fluid that builds up around the lung — fluid that causes people be short of breath, often have symptoms like cough

Bronchioloalveolar carcinoma (BAC) is an unusual subtype of lung cancer; medical oncologist Dr. Jack West reviews the evidence on the best systemic therapy to treat advanced, multifocal BAC.

Bronchioloalveolar carcinoma (BAC), also known as adenocarcinoma in situ, is an unusual subtype of lung cancer with its own appearance under a microscope and on imaging. Dr. Jack West introduces some of the basics of the unique features of BAC. Download PDF Transcript TranscriptOne of the unusual

Unfortunately, there is as much misinformation as good information about the unusual subtype of lung cancer known as bronchioloalveolar carcinoma (BAC) or adenocarcinoma in situ. Dr. Jack West reviews the top 5 myths. Download PDF Transcript TranscriptOne of the unusual subtypes of lung cancer is

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines oligometastatic lung cancer and describes the recent trend toward the use of stereotactic body radiation therapy to treat it.

Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.

Lung Cancer Video Library 2018

Dr. H. Jack West, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, President and CEO of GRACE offers updates to our Lung Cancer Video Library.In this video, Dr. West discusses chemotherapy and immunotherapy combinations in advanced squamous non-small cell lung cancer. We thank

Lung Cancer Video Library 2018

Dr. Sandip Patel, Associate Professor of Medicine at the Moores Cancer Center, UC San Diego Health, joined GRACE to offer updates to our Lung Cancer Video Library.In this video, Dr. Patel discusses the current status of tumor mutation burden.We thank the following organizations for their support

For this addition to the Lung Cancer Video Library, Dr. Millie Das joins GRACE to discuss current updates in treatment options for non small cell lung cancer.In this video, Dr. Das discusses the current leading treatment options for patients with low or negative tumor PDL1 expression and advanced

Lung Cancer Video Library 2020 - Emerging Molecular Targets in NSCLC, RET Fusions with Joshua Bauml MD

For this new addition to the GRACE Lung Cancer Video Library, Dr. Josh Bauml joins GRACE to discuss current updates in treatments for non small cell lung cancer.In this video, Dr. Bauml discusses updated information on emerging molecular targets in nsclc - RET fusions. To join the conversation

Lung Cancer Video Library 2020 - Emerging Molecular Targets in NSCLC - MET - with Joshua Bauml, MD

For this new addition to the GRACE Lung Cancer Video Library, Dr. Josh Bauml joins GRACE to discuss current updates in non small cell lung cancer.In this video, Dr. Bauml discusses updated information on emerging molecular targets in nsclc - MET. To join the conversation, visit https://cancergrace